Amgen said other operating expenses for the 3 and 9 months ended September 30, 2025 included Otezla intangible asset impairment charges of $400 million and $1.2 billion, respectively.

1. 01

   Amgen said other operating expenses for the 3 and 9 months ended September 30, 2025 included Otezla intangible asset impairment charges of $400 million and $1.2 billion, respectively.

2. 02

   The company cited lower net selling price of 38% for the 3-month period, resulting from the impact of the U.S. Medicare Part D redesign and increased 340B Program mix, and lower net selling price of 30% for the 9-month period as factors in the ENBREL sales decrease.

3. 03

   Amgen said financing activities cash used in the 9 months of 2025 was primarily driven by debt repayment of $5.0 billion, debt extinguishment of $683 million and dividend payments of $3.8 billion.

4. 04

   The company is contesting the 2010–2012 Notice seeking additional federal tax of approximately $3.6 billion and the 2013–2015 Notice seeking additional federal tax of approximately $5.1 billion and penalties of approximately $2.0 billion through the U.S. Tax Court, and expects a decision no earlier than the second half of 2026.

Key figures

Quarter ended September 30, 2025

Revenue

$9.6B

Operating income

$2.5B

Net income

$3.2B

EPS

$5.93

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.